Rapport Therapeutics, Inc.
UBS initiated coverage on Rapport Therapeutics (RAPP) with a 'Buy' rating and $71.00 price target. The company has a $1.42B market cap, GF Score of 14/100, and insider sales of $6.9M in 3 months. Analysts are optimistic about its precision medicines for neurological disorders, but profitability and growth metrics are weak.
Analysts updated ratings for General Dynamics (GD), Rapport Therapeutics (RAPP), and First Solar (FSLR). GD received a Hold rating with a $407 target; consensus is $425.62. RAPP got a Buy rating with a $66 target; consensus is $62.29. FSLR maintained a Buy rating with a $323 target; consensus is $268.25. All targets imply significant upside from current prices.
Rapport Therapeutics (RAPP) shares fell 17.6% after executives discussed clinical plans for RAP-219 at a summit, emphasizing pending Phase 2 data. Analysts maintained bullish ratings but highlighted binary risk. Insider sales and a weak market added to the decline. Shares hit an intraday low of $34.13, nearing the 52-week low of $23.75.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RAPP (Rapport Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RAPP coverage spans financial news, insider activity and market movers.
In the last 30 days, RAPP insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($562K). The most active reporter was Ceesay Abraham, Chief Executive Officer, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst initiation and Buy rating are likely to lift the stock.
Buy rating with a high target could drive buying pressure.
The slide reflects heightened investor anxiety over binary trial readout; further downside possible if data miss expectations.
Phase 3 entry suggests higher probability of approval, likely supporting near‑term price appreciation.
Advancing late‑stage trial supports valuation uplift.
AlphAI scores every news story that mentions RAPP with an AI model for sentiment and relevance, and aggregates insider trades from Rapport Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS initiated coverage on Rapport Therapeutics (RAPP) with a 'Buy' rating and $71.00 price target. The company has a $1.42B market cap, GF Score of 14/100, and insider sales of $6.9M in 3 months. Analysts are optimistic about its precision medicines for neurological disorders, but profitability and growth metrics are weak.
2 min readAnalysts updated ratings for General Dynamics (GD), Rapport Therapeutics (RAPP), and First Solar (FSLR). GD received a Hold rating with a $407 target; consensus is $425.62. RAPP got a Buy rating with a $66 target; consensus is $62.29. FSLR maintained a Buy rating with a $323 target; consensus is $268.25. All targets imply significant upside from current prices.
2 min readRapport Therapeutics (RAPP) shares fell 17.6% after executives discussed clinical plans for RAP-219 at a summit, emphasizing pending Phase 2 data. Analysts maintained bullish ratings but highlighted binary risk. Insider sales and a weak market added to the decline. Shares hit an intraday low of $34.13, nearing the 52-week low of $23.75.
2 min readRapport Therapeutics (RAPP) reached a 52-week high of $52.83. Its lead drug, RAP-219, entered Phase 3 trials for focal onset seizures, with strong clinical data showing sustained seizure reductions. The company reported a Q2 2026 net loss of $56.6M, up from $26.7M a year ago, with cash reserves of $436.1M. RAPP closed at $52.50, up 2.60%.
2 min readFive biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
3 min readCeesay Abraham (Chief Executive Officer) sold 18,921 shares of Rapport Therapeutics, Inc. (RAPP) at $49.57 ($0.94M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readYeleswaram Krishnaswamy (Chief Development Officer) sold 50,160 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $50.47 ($50.00–$51.06, $2.53M total) across 3 trades over 2026-08-24 to 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readCeesay Abraham (Chief Executive Officer) sold 51,499 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $47.25 ($45.97–$48.62, $2.43M total) across 5 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.
2 min readRapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results
6 min readRapport Therapeutics COO Cheryl Gault sold 10,000 shares of RAPP stock for about $416,000 in open-market trades on June 30, 2026, per an SEC Form 4. The sale reduced her direct holdings by 6.25% to 149,914 shares, worth about $5.9 million. The article notes RAPP shares were up 223.67% year over year as of July 1, 2026.
6 min read